Cargando…
Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics
Palivizumab is the only licensed and effective immunoprophylaxis (IP) available to prevent respiratory syncytial virus (RSV) infection in high-risk infants including infants born at ≤35 weeks’ gestational age (wGA). In 2014, the American Academy of Pediatrics stopped recommending IP for otherwise he...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group US
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271636/ https://www.ncbi.nlm.nih.gov/pubmed/32499597 http://dx.doi.org/10.1038/s41372-020-0689-y |